08:21:25 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Oncolytics Biotech Inc (2)
Symbol ONC
Shares Issued 142,325,222
Close 2018-05-24 C$ 0.95
Market Cap C$ 135,208,961
Recent Sedar Documents

Oncolytics to study myeloma treatment with USC

2018-05-25 08:00 ET - News Release

Mr. Michael Moore reports

ONCOLYTICS BIOTECH ANNOUNCES RESEARCH COLLABORATION WITH THE KECK SCHOOL OF MEDICINE OF USC COMBINING REOLYSIN WITH KEYTRUDA, VELCADE AND DEXAMETHASONE

Oncolytics Biotech Inc. will collaborate with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda, Velcade and dexamethasone to treat multiple myeloma. This study, facilitated by Dr. Kevin Kelly, associate professor of clinical medicine, is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple myeloma and will be conducted at the USC Norris Comprehensive Cancer Center. It will add Keytruda, Merck's anti-PD-1 therapy, to the regimen.

The study continues to build on the company's I-O program and is now its third combination in human trials after the previously announced second line pancreatic cancer study -- also with Keytruda -- and the multiple myeloma study in combination with Celgene's Imnovid and Revlimid. Oncolytics will supply pelareorep for the study and Merck will supply the Keytruda.

The combination of proteasome inhibitors and pelareorep has been demonstrated to increase PD-L1 expression on multiple myeloma cells and to recruit T-cells to the bone marrow. This study will enroll patients with relapsed-refractory multiple myeloma and will primarily evaluate overall response rate, as well as safety and tolerability. It will also provide important biomarker data determined by analysis of pretreatment and posttreatment biopsies and blood-based immune markers.

Final study design and other details will be announced upon enrolment of the first patient, expected in the second half of 2018.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing Reolysin, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype -- turning cold tumours hot -- through innate and adaptive immune responses to treat a variety of cancers.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.